Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Trial Identifier: D419MC00006
Sponsor: AstraZeneca
NCTID:: NCT05826366
Start Date: June 2023
Primary Completion Date: November 2025
Study Completion Date: November 2025
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Aichi, Japan
Japan Akita, Japan
Japan Aomori, Japan
Japan Chiba, Japan
Japan Ehime, Japan
Japan Fukuoka, Japan
Japan Fukushima, Japan
Japan Gifu, Japan
Japan Gunma, Japan
Japan Hiroshima, Japan
Japan Hokkaido, Japan
Japan Hyogo, Japan
Japan Ibaraki, Japan
Japan Ishikawa, Japan
Japan Iwate, Japan
Japan Kagawa, Japan
Japan Kagoshima, Japan
Japan Kanagawa, Japan
Japan Kochi, Japan
Japan Kumamoto, Japan
Japan Kyoto, Japan
Japan Mie, Japan
Japan Miyagi, Japan
Japan Miyazaki, Japan
Japan Nagano, Japan
Japan Nagasaki, Japan
Japan Nara, Japan
Japan Niigata, Japan
Japan Oita, Japan
Japan Okayama, Japan
Japan Osaka, Japan
Japan Saitama, Japan
Japan Shiga, Japan
Japan Shimane, Japan
Japan Shizuoka, Japan
Japan Tochigi, Japan
Japan Tokushima, Japan
Japan Tokyo, Japan
Japan Tottori, Japan
Japan Toyama, Japan
Japan Wakayama, Japan
Japan Yamagata, Japan
Japan Yamaguchi, Japan
Japan Yamanashi, Japan